Article2018-02-06T17:27:34+00:00

The Appeal of Value Assessment at ISPOR 2018

At this year’s ISPOR, Precision Xtract’s Larry Blandford and Precision Health Economics’ Jason Shafrin met with BioPharm Insights to illuminate the importance of shifting to value-based assessment and examine reasons why US payers are slow to adopt the model.

To read the full article, please click below.

BioPharm Insight Value-based Assessments ISPOR 2018

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK